默沙东注射用头孢洛生他唑巴坦钠(卓利达)正式在华上市

南方财经网
Aug 13

  南方财经8月13日电,记者获悉,默沙东今日宣布,其新型头孢菌素酶抑制剂复方制剂——注射用头孢洛生他唑巴坦钠(注册商标:卓利达®)正式在中国境内上市,为临床应对铜绿假单胞菌(PA)和超广谱β-内酰胺酶肠杆菌(ESBL-E)等复杂耐药菌的感染提供了全新选择。

  注射用头孢洛生他唑巴坦钠(注册商标:卓利达®)于今年2月获中国国家药品监督管理局(NMPA)批准,用于与甲硝唑联合治疗成人和儿童(出生至18岁以下)患者由敏感革兰阴性和革兰阳性微生物引起的复杂性腹腔感染(cIAI);治疗成人和儿童(出生至18岁以下)患者由敏感革兰阴性微生物引起的复杂性尿路感染(cUTI)(包括肾盂肾炎);治疗成人(18岁及以上)患者由敏感革兰阴性微生物引起的医院获得性细菌性肺炎(HABP)和呼吸机相关性细菌性肺炎(VABP)。(21世纪经济报道)

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10